Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMS274E)

Drug Name
MORF-057 Drug Info
Indication
Disease Entry ICD 11 Status REF
Crohn disease DD70 Phase 2 [1]
Ulcerative colitis DD71 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMS274E

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Integrin alpha-4/beta-7 (ITGA4/B7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MLN0002 DMP2LZ8 Crohn disease DD70 Approved [2]
TRK-170 DM13G5R Inflammatory bowel disease DD72 Phase 2 [3]
PN-943 DMUZLKW Ulcerative colitis DD71 Phase 2 [4]
GS-1427 DMDDBG1 Inflammation 1A00-CA43.1 Phase 1 [5]
TR-14035 DMWD39E Multiple sclerosis 8A40 Discontinued in Phase 1 [6]
R1295 DMT8V9G Rheumatoid arthritis FA20 Discontinued in Phase 1 [7]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Integrin alpha-4/beta-7 (ITGA4/B7) TT7ZMI1 ITA4_HUMAN-ITB7_HUMAN Antagonist [1]

References

1 ClinicalTrials.gov (NCT05291689) A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Tolerability of MORF-057 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-1). U.S.National Institutes of Health.
2 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
3 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
4 Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of alpha4beta7, in Healthy Volunteers. Clin Pharmacol Drug Dev. 2021 Nov;10(11):1263-1278.
5 Clinical pipeline report, company report or official report of Gilead
6 Pharmacokinetics and metabolism of TR-14035, a novel antagonist of a4ss1/a4ss7 integrin mediated cell adhesion, in rat and dog. Xenobiotica. 2005 Apr;35(4):373-89.
7 Vedolizumab: an 47 integrin inhibitor for inflammatory bowel diseases.Ann Pharmacother.2014 Dec;48(12):1629-35.